SGLT2 inhibitors have demonstrated great success in the treatment of type 2 diabetes mellitus, in addition to having been found to have advantageous effects on the cardiovascular system, kidneys, and Alzheimer’s disease (Rieg and Vallon, 2018; Esterline et al., 2020; Nishimura et al., 2022). Here, SLC5A2 is linked to early-onset autosomal dominant Alzheimer disease.